• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Versant launches biotech incubator in N.Y.

Versant launches biotech incubator in N.Y.

August 26, 2015
CenterWatch Staff

Versant Ventures, a San Francisco-based global healthcare venture capital firm, has launched its third biotech incubator, Highline Therapeutics, and promoted Carlo Rizzuto to manage the firm’s newly established New York base.

Rizzuto will lead investments in innovative biotech startups as part of Versant’s strategy to expand its operations to New York and intensify investment activities in the broader Northeast. Based in Highline Therapeutics’ office in Manhattan, Rizzuto will work with Versant’s team of investment professionals and entrepreneurs to leverage the region’s world-class science and establish a broad portfolio of startups. A New York native, Rizzuto recently relocated to the city from Basel, Switzerland, where he previously operated from Versant’s European headquarters.

Since mid-2014, Rizzuto has led the effort to establish Highline Therapeutics as an engine for launching multiple biotech startups. Partnerships have been formed with some of the leading local academic institutions and several formal programs will be announced over the coming months.

Rizzuto said, “New York City’s researchers attract a significant amount of NIH funding, yet the city receives a relatively modest portion of available biotech venture capital funding. In the broader geographic region, there is a wealth of additional top-tier universities, such as Penn, Yale and Johns Hopkins. We are excited to partner with these institutions and build innovative startups together.”

In 2012, Rizzuto joined Versant as operating principal and played crucial roles in a number of promising investments including GenSight, Piqur, Anokion and Mosaic. Most recently, Rizzuto assumed the leadership role for the Anokion $760 million “build-to-buy” deal with Astellas in the field of autoimmune disease. He joined Versant from Novartis where he served in leadership roles in the drug development organization.

Highline is the latest addition to Versant’s network of regional discovery engines, which includes Blueline Bioscience in Toronto and Inception Sciences in San Diego, Vancouver and Montreal. Highline reflects the firm’s approach to more effectively identify breakthrough therapeutic discoveries directly from academic sources. Versant’s local incubation model has led to several successful outcomes, most recently in Quanticel Pharmaceuticals, which announced its acquisition by Celgene earlier this year. Quanticel was built from academic programs at Stanford University that were identified by Versant’s Bay Area team.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing